Background and objective: Non-invasive ventilation (NIV) improves clinical outcomes in hypercapnic acute exacerbations of COPD (AECOPD), but the optimal model of care remains unknown. Methods: We conducted a prospective observational noninferiority study comparing three models of NIV care: general ward (Ward) (1:4 nurse to patient ratio, thrice weekly consultant ward round), a high dependency unit (HDU) (1:2 ratio, twice daily ward round) and an intensive care unit (ICU) (1:1 ratio, twice daily ward round) model in three similar teaching tertiary hospitals. Changes in arterial blood gases (ABG) and clinical outcomes were compared and corrected for differences in AECOPD severity (Blood urea > 9 mmol/L, Altered mental status (Glasgow coma scale (GCS) < 14), Pulse > 109 bpm, age > 65 (BAP-65)) and comorbidities. An economic analysis was also undertaken. Results: There was no significant difference in age (70 AE 10 years), forced expiratory volume in 1 s (FEV 1 ) (0.84 AE 0.35 L), initial pH (7.29 AE 0.08), partial pressure of CO 2 in arterial blood (PaCO 2 ) (72 AE 22 mm Hg) or BAP-65 scores (2.9 AE 1.01) across the three models. The Ward achieved an increase in pH (0.12 AE 0.07) and a decrease in PaCO 2 (12 AE 18 mm Hg) that was equivalent to HDU and ICU. However, the Ward treated more patients (38 vs 28 vs 15, P < 0.001), for a longer duration in the first 24 h (12.3 AE 4.8 vs 7.9 AE 4.1 vs 8.4 AE 5.3 h, P < 0.05) and was more cost-effective per treatment day ($AUD 1231 AE 382 vs 1745 AE 2673 vs 2386 AE 1120, P < 0.05) than HDU and ICU. ICU had a longer hospital stay (9 AE 11 vs 7 AE 7 vs 13 AE 28 days, P < 0.002) compared with the Ward and HDU. There was no significant difference in intubation rate or survival. Conclusion: In acute hypercapnic Chronic obstructive pulmonary disease (COPD) patients, the Ward model of NIV care achieved equivalent clinical outcomes, whilst being more cost-effective than HDU or ICU models.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) imposes a huge economic burden on healthcare systems worldwide mainly as a result of acute exacerbations. 1 Noninvasive ventilation (NIV) is a proven therapy for acute exacerbations of COPD (AECOPD) complicated by acute hypercapnic respiratory acidosis. 2, 3 Randomized controlled trials 3, 4 and meta-analysis 5 demonstrate that NIV halves the mortality and intubation rate and reduces hospital length of stay, [2] [3] [4] 6 achieving more rapid improvements in physiological parameters compared with standard medical treatment, 5 such that NIV has now surpassed invasive mechanical ventilation as the initial form of respiratory support in the USA. 7, 8 The model of NIV service delivery in the acute hospital setting has evolved over the last 20 years. Earlier studies were performed in the emergency department or intensive care unit (ICU) setting (nursing to patient ratio 1:1 and continuous monitoring). 4 Other studies utilized a high dependency unit (HDU) setting to deliver NIV (nursing to patient ratio 1:2, continuous monitoring). 9 However, a pivotal study demonstrated that NIV could be applied successfully to COPD patients on a respiratory or general medical ward (nursing to patient ratio 1:12, no continuous monitoring). 3 Furthermore, a subsequent economic analysis of this study demonstrated cost savings for those treated with NIV compared to those who did not. 10 In clinical practice, NIV service location and protocols may vary according to local resources, particularly the availability of ICU beds. The question of where NIV should be delivered has been much debated in the literature. [11] [12] [13] To our knowledge, no direct comparison of NIV models of care (general ward (Ward), HDU and ICU) has ever been undertaken. We hypothesised that a Ward-based NIV service would produce equivalent clinical outcomes compared with an HDU-or ICUbased model and be more cost-effective, when treating hypercapnic AECOPD. In metropolitan Melbourne, three tertiary hospitals of similar size operated with different models of NIV care (Ward, HDU and ICU) providing an opportunity for comparison.
METHODS
A prospective observational non-inferiority study was performed in three government-funded, tertiary referral, university-based, teaching hospitals, each containing 350-500 beds, 14 over a 14-month period (March 2011-May 2012). Ethics approval was obtained from the institutional ethics committee at all three hospitals and the trial was registered with clinical trials registry (ACTRN12613000011785). Each hospital had an established NIV service (greater than 5 years) operating under a Ward, HDU-and ICU-based model of care. Information regarding the model was collected for each hospital, including: nurse to patient ratio; registrar, physician and respiratory nurse specialist allocation to service; frequency of physician ward round and NIV equipment. Inclusion criteria were: all patients admitted with a primary diagnosis of AECOPD (physician diagnosis) complicated by acute hypercapnic respiratory acidosis (arterial pH < 7.35 and partial pressure of CO 2 in arterial blood (PaCO 2 ) > 45 mm Hg) and receiving NIV during their admission. COPD patients receiving NIV post-invasive mechanical ventilation were excluded.
A Microsoft Access database was created to record data prospectively in a standardized manner at the three hospitals. Patient demographics, medication, lung function within 12 months and relevant COPD comorbidities (e.g. cardiac, neurological, diabetes, osteoporosis and depression) 15, 16 were collected. BAP-65 scores (based upon Blood urea > 9 mmol/L, Altered mental status (Glasgow coma scale (GCS) < 14), Pulse > 109 bpm, age > 65) were calculated from initial emergency department evaluations to provide a validated measure of COPD exacerbation severity. 17 The primary outcome measure was the increase in pH and reduction in PaCO 2 with NIV treatment. Secondary outcome measures were: total number of patients treated, hospital length of stay, survival, intubation rate, treatment outcome, NIV machine settings and adherence. Treatment outcomes were classified as: (i) unable to tolerate NIV, (ii) improved on NIV and ceased, (iii) deteriorated on NIV and intubated, (iv) deteriorated but NIV continued for palliation and (v) patient palliated and NIV ceased. A maximum of two admissions per patient were included in the data for analysis.
An economic analysis was performed using direct and indirect costs for each patient admission including medical, nursing, allied health, pharmacy, pathology, radiology and bed costs. These figures were generated by each hospital finance department and used for reimbursement via government funding. Bed day costs were calculated for each centre based on personnel and overhead costs for each bed. Equipment costs were calculated on disposable and non-disposable (capital) equipment.
Statistical analysis
Results are given as mean AE SD for normally distributed data. Three-way analysis of variance (ANOVA) (log conversion) was used to compare means for clinical outcomes and costs between the three models. Cost per total admission, per day of admission and per day of NIV treatment were calculated. Chi-square test was used to compare proportions. Sixteen patients were required at each centre to achieve a power of 80% with a two-sided alpha of 0.05 for the primary outcome variables. Regression analysis was used to construct models for significant findings to correct for the effects of co-morbidities and disease severity (BAP-65).
RESULTS

Models of care
Medical, nursing support and ventilator type for all three models are summarized in Table 1 . Patients were admitted via the emergency department and transferred either to the Ward, HDU or ICU depending on the care model available in the hospital. The Ward model included a respiratory nurse specialist with a background in ICU and respiratory nursing and supported by a geographically separate ICU for deteriorating patients. During the study, 72% of AECOPD patients were managed on the respiratory ward and 28% on general medical wards. The HDU model also included a respiratory nurse specialist with a background in ICU and respiratory nursing and ICU support was available in a separate location within the hospital. The ICU model managed all NIV patients with 1:1 nursing ratio and twice daily ICU registrar and consultant ward rounds. In all care destinations, arterial blood gases (ABG) were taken at baseline, 1, 4, 24 h and as clinically indicated thereafter or until pH > 7.35 was achieved. Arterial lines were utilized in some ICU patients. Portable bedside oximetry monitoring was available in the Ward model, whereas dedicated cardiopulmonary bedside monitors were used in HDU and ICU models.
Patient demographics
Patient demographics, BAP-65 scores and comorbidities are summarized in Table 2 . There was no significant difference in patient age, gender, forced expiratory volume in 1 s (FEV 1 ) , BMI, baseline pH and PaCO 2 , BAP-65 score or COPD co-morbidities between the three models of care.
Primary outcomes
All three models of care demonstrated a significant improvement in ABG parameters with an increase in pH (0.11 AE 0.08 vs 0.10 AE 0.1 vs 0.09 AE 0.10, P = 0.85) (Fig. 1A) and a decrease in PaCO 2 (14 AE 19 vs 13 AE 18 vs 10 AE 19 mm Hg, P = 0.88) (Fig. 1B) for the Ward, HDU and ICU models, respectively. The Ward model was non-inferior to HDU and ICU models (P = 0.2 and 0.6, respectively) including after correction for BAP-65 and co-morbidities. There was no significant difference in the mean number of days between the first and last ABG across the three models (3.2 AE 5.4 vs 3.4 AE 5.8 vs 3.7 AE 3.3, P = 0.926) for the Ward, HDU and ICU models, respectively.
Secondary outcomes
A total of 81 patients were managed during 92 encounters with NIV (11 patients admitted twice across the three hospitals). The Ward model managed significantly more NIV encounters than HDU and ICU when adjusted for hospital size (Fig. 2) . Patients in the Ward model received significantly more hours of NIV during the first 24 h of admission than the HDU and ICU models (12.3 AE 4.8 vs 7.9 AE 4.1 vs 8.4 AE 5.3 h, P = 0.006). Hospital length of stay was shorter for patients receiving NIV in the Ward and HDU when compared with ICU model (9 AE 11 vs 7 AE 7 vs 13 AE 28 days, P < 0.002) (Fig. 3) .
NIV ceased in the majority of patients because of clinical improvement in each model (76 vs 77 vs 75%, P = 0.38) in the Ward versus HDU or ICU models. There was no significant difference in intubation rates (2 vs 0 vs 12.5%, P = 0.11) or mortality rates (11 vs 3 vs 6%, P = 0.59) between the three models, nor were there differences in relation to 'unable to tolerate NIV' (4 vs 3 vs 0%, P > 0.05) or NIV used for palliation (9 vs 3 vs 6%, P > 0.05), even when corrected for the effects of BAP-65 and co-morbidities All results are reported as mean (SD) except for number of patients (n) and gender (proportion). FEV 1 (n = 31, 29 and 9 for the Ward, HDU and ICU, respectively).
† Adjusted for hospital size. BAP-65, Blood urea > 9 mmol/L, Altered mental status (Glasgow coma scale (GCS) < 14), Pulse > 109 bpm, age > 65; FEV 1 , forced expiratory volume in 1 s; HDU, high dependency unit; ICU, intensive care unit; PaCO 2 , partial pressure of CO 2 in arterial blood.
NIV settings
The Ward used the Synchrony (Respironics, Murraysville, PA, USA), HDU the Carina (Drager, Lubeck, Germany) and ICU the Evita XL (Drager) for NIV. Starting pressures were as per each institution's guidelines with pressures adjusted depending on comfort, ABG and clinical response. A full face mask was used in all three hospitals. Oxygen was added to maintain pulsatile arterial oxyhaemoglobin saturation (SpO 2 ) at 88-92%. No significant difference was found in the final Inspiratory Positive Airway Pressure (IPAP) settings (15 AE 1 vs 17 AE 1 vs 14 AE 1 cm H 2 O, P = 0.06) or the back-up respiratory rate (8 AE 1 vs 12 AE 1 vs 7 AE 3 breaths/min, P = 0.009) for the Ward, HDU or ICU models. However, the final Expiratory Positive Airway Pressure (EPAP) setting (7 AE 2 vs 8 AE 3 vs 5 AE 2 cm H 2 O, P = 0.02) was lower in the ICU when compared with the Ward and HDU models.
Economic analysis
Total costs for the Ward and HDU models were significantly less than ICU when analysed for total hospital admission ($AUD 9,002 AE 5,982 vs 9,213 AE 5,303 vs 27,485 AE 11,654, p < 0.001) and per day of hospital admission ($AUD 1,231 AE 382 vs 1,745 AE 2,673 vs 2,386 AE 1,121, P < 0.001). These differences remained significant when corrected for the effects of BAP-65 and co-morbidities. Total costs for the Ward model were significantly less than HDU model when analysed per day spent on NIV ($AUD 1,400 AE 917 vs 2,754 AE 2,810, P < 0.001) and remained significant after correction for BAP-65 and co-morbidities (regression model, P < 0.001).
DISCUSSION
In this study of hypercapnic AECOPD, a Ward-based model of NIV care achieved equivalent clinical outcomes (i.e. improvements in pH and PaCO 2 ) compared with HDU and ICU models whilst also being more cost-effective. Moreover, the Ward model treated significantly more patients than ICU, with a trend compared with HDU adjusted for hospital size. The Ward model also delivered more hours of NIV during the first 24 h of admission and was more cost-effective (per admission, per hospital day and per hospital day on NIV) than the HDU and ICU models. Conversely, the ICU model had a longer hospital length of stay despite the intubation and mortality rates not differing across the three models. Importantly, all of these differences remained significant after correcting for COPD exacerbation severity (BAP-65) and co-morbidities. To our knowledge, this is the first study to demonstrate the equivalence of three NIV models of care, but with the Ward model treating a greater number of patients more cost-effectively.
Many findings in the current study are comparable to the two largest randomized controlled studies of NIV in COPD, conducted in the ICU 4 and Ward. 3, 18 The range of initial pH (7.27-7.31) and PaCO 2 (65-77 mm Hg) were similar across all the three studies. In the current study, pH increased by 0.1 and PaCO 2 decreased by 12 mm Hg over a mean of 3 days across the Ward, HDU and ICU. This compares to an increase in pH of 0.03-0.04 and a decrease in PaCO 2 of 2-4 mm Hg after 1-4 h in the previous studies.
3,4 NIV was administered for a mean of 8-12 h during the first 24 h compared to 6-8 h in prior studies. 3, 4, 6 Hospital length of stay was 8-14 days, dependent on location, compared with 10-14 days in the previous ward-based study. 3, 18 The mortality rate in the current study varied between 0% and 11% across the three groups compared with 9% to 10% to 23% in the previous studies. 3, 4, 18 The mortality rate for the Ward model reflected one patient who received a transplant and died during the admission whilst the other four patients used NIV as a ceiling of treatment for palliation. The rate of intubation in the ICU group was 20% as compared with 15-26% in the previous studies. 3, 4 However, there were some significant differences. The intubation rate in the current Ward and HDU models (0-2%) was lower. This may be explained by a greater emphasis on palliation with NIV outside the ICU as a ceiling of care. Selection bias may also have resulted in patients less likely to require intubation being admitted to the general ward and HDU models; however, the equivalent markers of disease severity across the three models argue against this.
The study findings have several potential clinical implications. First, a Ward model of care may offer greater availability of NIV to COPD patients without compromising clinical outcomes. Underutilization of NIV has been reported in the acute hospital setting. 19 British Thoracic Society guidelines suggest that NIV should be available 24 h a day for all hospitals likely to admit such patients. Presumably, greater bed capacity on a respiratory and general medical ward would allow treatment to be offered to more patients. Furthermore, this could free up ICU beds for the most complex patients, particularly those requiring invasive mechanical ventilation.
Second, we observed NIV delivery to be more costeffective in the Ward model. Part of this effect was due to a shorter length of stay and lower daily costs compared with ICU and HDU, respectively. General ward model of NIV care for AECOPD is already recognized as cost-saving compared with standard therapy due to a reduction in ICU admissions. 3 The current results extend these findings by demonstrating that a Ward or HDU model with ICU support as required is more costeffective than an exclusive ICU model. Several countries have already implemented Ward or HDU models of care to cope with the demand. 20 This study supports the appropriateness of these models of care from a clinical and cost-effectiveness point of view.
Third, managing these patients in ICU may result in a longer length of stay than on the ward. In our study, the Ward model delivered more hours of NIV during the critical first 24 h which may have contributed to the shorter hospital length of stay. The ICU model patients may be thought to be more unwell than the general ward or HDU model cohort to explain the longer length of stay. However, baseline physiological parameters, BAP-65 score and co-morbidities did not differ between the groups making this unlikely. Anecdotally, patients in the ICU model cohort ceased NIV and then underwent a period of observation to ensure stability before being discharged to the ward. This could increase hospital length of stay. Discharge planning may be more streamlined in the general ward model for COPD patients with earlier mobilization and less sleep deprivation than in the ICU. 21, 22 However, we can only speculate on the underlying reasons as they were not formally assessed in this study.
Despite the apparent benefits of a Ward model of NIV care, there are several caveats that need to be considered before implementing this particular model of care. Patient selection is critical. COPD patients with a mild-to-moderate acidosis were included in the current study and the study by Plant et al. 3 Highly trained and experienced staff including a specialist respiratory physician, dedicated respiratory registrar and specialist respiratory nurse were included in the general ward model. The general ward and HDU models did not function in isolation: they were supported by an ICU team with clinical pathways in case of clinical deterioration.
This study has several strengths. As far as we are aware, this is the first study to directly compare three different models of NIV care (general ward, HDU and ICU) including baseline characteristics, clinical outcomes and cost-effectiveness. Data were collected prospectively in a 'real-world' setting with the three tertiary metropolitan hospitals offering ideal conditions for a natural experiment.
The limitations of the study include the observational design without randomization. Variability in COPD admission and management practices across the three centres could explain some of the results. However, recognizing this constraint, all three groups had similar baseline characteristics and any differences were controlled for during statistical analysis. A randomized controlled study could not realistically be performed in a single centre due to overlap in patient treatment across general ward, HDU and ICU. These results may not be generalizable across other health systems which may, for instance, have different costings for resources. However, the cost savings in the current study are considerable (e.g. $AUD1155 per day of admission for Ward vs ICU) and reflect ICU staffing costs, so are likely to be reproducible at other centres. Indeed, further work by our group has demonstrated that converting from an ICU to a Ward model of care has resulted in increased availability of NIV treatment with considerable cost savings.
In summary, this study demonstrates that a Ward model of NIV care produces equivalent clinical outcomes in hypercapnic AECOPD compared with HDU and ICU whilst being more cost-effective.
